Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Myeloma Multiple Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

4 recruiting trials for Myeloma Multiple. Eligibility criteria explained in plain English.

TrialFinderData lists 4 Myeloma Multiple clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Every phased trial in this set is Phase 1 (1 of the listed studies); the remaining records are observational or have no phase recorded on ClinicalTrials.gov.

Research is led by Azienda Ospedaliero-Universitaria di Parma (1), IRCCS Azienda Ospedaliero-Universitaria di Bologna (1), K36 Therapeutics, Inc. (1), among the most active sponsors registered for these trials.

The most frequently studied intervention is Multi-omics analyses (other, 1 trial), followed by Functional tests, Cohort A1 & A2: KTX-1001.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
4
Total Trials
4
Recruiting Now
0
Phase 3 Trials
4
Sponsors

Track Myeloma Multiple trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT07445438

Feasibility of a Multi-omics Platform for Hematological Malignancies

This is a biological study based on a collaborative effort involving several Italian haematology centres (including the coordinating centre). The study will be conducted...

Sponsor: Azienda Ospedaliero-Universitaria di ParmaEnrolling: 10401 location
RECRUITINGNCT07582354

MMAPPIN' Study: Multiple Myeloma Analysis For Patient-specific Insights to Dissect Disease Heterogeneity

This is a single-center, observational study in patients with multiple myeloma, conducted both retrospectively and prospectively. The study aims to improve understanding of the...

Sponsor: IRCCS Azienda Ospedaliero-Universitaria di BolognaEnrolling: 5201 location
RECRUITINGPhase 1NCT05651932

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as...

Sponsor: K36 Therapeutics, Inc.Enrolling: 16520 locations
RECRUITINGNCT07205523

High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT)

The High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT) study is the first prospective real-world cohort of hematologic diseases and transplantation in the...

Sponsor: Yigeng Cao,MD,PhDEnrolling: 10001 location

Frequently Asked Questions

There are currently 4 clinical trials for Myeloma Multiple, with 4 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Myeloma Multiple, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Myeloma Multiple, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.